Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies
Marco Ruella(Parker Institute for Cancer Immunotherapy), Marcela V. Maus(Center for Cancer Research)
Cited by 281
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
|Nature Biotechnology|2019|724
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554